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THE GROWTH PLATE AS A NOVEL MODEL SYSTEM FOR
DRUG DISCOVERY IN OSTEOARTHRITIS: CALCITONIN
AUGMENTS CARTILAGE FORMATION AND ATTENUATES
CARTILAGE DEGRADATION
A.K. Olsen1, K. Henriksen1, E.U. Sumer1, C. Christiansen2,
P. Qvist1, M.A. Karsdal1
1Nordic Bioscience, Herlev, Denmark, 2CCBR, Ballerup,
Denmark
Purpose: Osteoarthritis is a complicated process comprising os-
teoclast, osteoblast and chondrocyte pathologies. These include
osteoclastic bone resorption, osteoblastic bone formation, chon-
drocyte hypertrophy and subsequent cartilage degradation. At
present, there are no ex vivo models which allow for investigation
of the combined metabolism of all the implicated cell types in
one single simple ex vivo model.
The remodelling in the growth plates may partly resemble the
cartilage pathology during OA progression. Therefore we de-
veloped a growth plate model in which parameters of the OA
pathology involving both bone and cartilage parameters can be
investigated. We developed a new ELISA assay and techniques
to assess MMP derived cartilage degradation, cartilage formation
as well as osteoclastic bone resorption.
Methods: Tibiae were dissected from embryonic NMRi mice
at day 17 post vaginal plug, as previously described. The ex-
periment was designed with a paired control. One tibia was
stimulated with 100nM salmon calcitonin (sCT) and compared to
vehicle treatment. The experiment was performed in 4 replicates.
The ex vivo tissue was cultured in 0.1% BSA in alpha-MEM for 7
days with refreshment of medium other day.
We assessed parameters of tissue turnover in the conditioned
medium by an array of ELISA assays 1) bone resorption by CTX-
I 2) MMP mediated collagen type II degradation by CTX-II 3)
cartilage formation by pro-collagen type II, PIIb. For clarification,
conditioned medium was measured at all days, and data are
accumulated over the entire culture period.
Results: Calcitonin inhibited bone resorption (CTX-I) (P<0.01)
by 50%, and collagen type II degradation (CTX-II) by 50%. Col-
lagen type II formation (PIIb) was stimulated by 75% (P<0.01).
Conclusions: By combining a novel ex vivo tissue culture with
biochemical markers that are specific products of enzyme activity,
we have developed a biological model in which most of the
parameters in the progression of OA can be investigated. This
model system allows for accurate profiling of hormones and other
molecules that positively could affect the disease mechanisms of
OA and therefore progression of OA.
Calcitonin has been suggested to be a possible treatment for OA.
Calcitonin inhibited cartilage and bone degradation, and stimu-
lated cartilage formation. Calcitonin affects both osteoclast and
chondrocyte metabolism, and seems to shift chondrocyte activity
toward a cartilage formation rather than a cartilage degradation
phenotype.
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CROSSTALK BETWEEN INTERLEUKIN-1 AND
SPHINGOLIPIDS: SPHINGOSINE-1-PHOSPHATE
ABROGATES NITRIC OXIDE PRODUCTION AND LOSS OF
GLYCOSAMINOGLYCANS IN BOVINE CHONDROCYTES
M.H. Stradner, J. Hermann, W.B. Graninger
Department of Internal Medicine, Division of Rheumatology,
Medical University of Graz, Graz, Austria
Purpose: Sphingosine-1-Phosphate (S1P) is a bioactive sph-
ingolipid, known to influence inflammation and wound healing.
High levels of S1P are found in osteoarthritic joints and S1P
potently stimulates chondrocyte proliferation by binding to its
specific receptors. In our study, we focused on the interactions
of S1P and Interleukin 1 (IL-1).
Methods: Cartilage explants were obtained from bovine
metacarpophalangeal joints and chondrocytes were isolated us-
ing collagenase B. Explants and cells were cultured in Ham’s
F-12/DMEM (1:1) and 10% FCS. Upon confluence cells were
serum starved for 24 hours and incubated with S1P alone or
in combination with IL-1β. Expression of inducible nitric oxide
synthase (iNOS) was evaluated using real-time PCR and im-
munoblot. Cell culture supernatants were tested for nitrite using
Griess reaction, thereby estimating enzyme activity of iNOS.
Loss of glycosaminoglycans (GAG) from cartilage explants after
48h of treatment was determined using dimethyl-methylen blue
assay.
Results: S1P decreased iNOS expression in unstimulated and
IL-1β stimulated chondrocytes in a dose dependent manner.
The inductive effect of IL-1β on iNOS mRNA was significantly
inhibited by S1P (p<0.05). At concentrations of 0.1μM S1P
reduced the stimulatory effect of IL-1β by 50 ± 3% (mean ±
SD). Furthermore, concentrations of 0.5 μM S1P reduced iNOS
expression to 19 ± 10% (mean ± SD) of initial IL-1β induction.
Immunoblotting confirmed these results. iNOS activity induced
by IL-1β was reduced to 25 ± 13% (mean ± SD, p<0.05) upon
treatment with 0.5μM S1P. Furthermore IL-1β mediated GAG
depletion from cartilage explants was completely abrogated at a
concentration of 3μM S1P (p<0.05).
Conclusions: In addition to the proliferative effect of S1P, our
data demonstrate that S1P blocks iNOS expression, NO for-
mation and GAG depletion in IL-1β treated chondrocytes. S1P
formation in osteoarthritic joints may therefore present a tissue
reaction against the effects of IL-1.
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THE ROLE OF THE TRANSCRIPTION FACTOR C/EBP IN
DOWN-REGULATION OF CARTILAGE MATRIX GENE
EXPRESSION
T. Imamura1, C. Imamura2, A. McAlinden2, Y. Iwamoto1,
L.J. Sandell2
1Kyushu Univ., Fukuoka, Japan, 2Washington Univ., St. Louis,
MO
Purpose: Rheumatoid arthritis (RA) is characterized by an in-
flammatory process in the synovium resulting progressive de-
struction of the affected joints. Pro-inflammatory cytokines such
as Tumor Necrosis Factor (TNF)-alpha and Interleukin (IL)1beta
directly inhibit cartilage gene expression and maintain the inflam-
matory process, causing functional impairment. To investigate
the mechanism of inhibition, we have used the gene encod-
ing cartilage-derived retinoic acid-sensitive protein (CD-RAP).
CD-RAP is a small secreted matrix protein expressed in de-
veloping and adult cartilage and by chondrocytes in culture. It
was originally cloned as an mRNA co-regulated with Col2a1
in cartilage and it provides a good model for cartilage gene
transcription. We have shown that the expression of Cd-rap is
repressed by IL-1beta mediated through a C/EBP site at -2088
to -2075 bp. Recently, we reported that the co-activator protein
CBP/p300 stimulates Cd-rap gene expression by a mechanism
whereby it sequesters the negative regulator C/EBP, rendering
it inactive. Additional up-regulation of the Cd-rap gene is due
to inactivation of C/EBP binding at second C/EBP site (-1060
to -1047 bp). Here, we found this site is responsible for gene
repression by TNF-alpha. Inactivation of this site completely in-
hibits down-regulation by TNF-alpha. Furthermore, the removal
of C/EBP inhibition by CBP/p300 and by C/EBP mutation allows
the CBP/Sox9 interaction to be more effective in increasing gene
expression.
